13 Results

People

  1. Lesokhin
    Lesokhin
  2. Giralt
    Giralt
  3. Mailankody
    Mailankody
  4. Usmani
    Usmani
  5. Hassoun
    Hassoun
  6. Landgren
    Landgren
  7. Maclachlan
    Maclachlan
  8. Afifi
    Afifi
  9. Carroll
    Carroll
  10. Chung
    Chung

Groups

  1. Center for Hematologic Malignancies (12)
  2. Department of Medicine (12)
  3. Hematologic Malignancies, Division of (12)
  4. Myeloma (10)
  5. Hematologic Malignancies Research (8)
  6. GME, Medicine (5)
  7. Graduate Medical Education (5)
  8. Bone Marrow Transplant (4)
  9. Survivorship Research (3)
  10. Department of Pathology and Laboratory Medicine (2)
  1. "elotuzumab"
Formats
  1. Journal Article (10)
  2. Review (2)
  3. Editorial (1)
Groups
  1. Center for Hematologic Malignancies (12)
  2. Department of Medicine (12)
  3. Hematologic Malignancies, Division of (12)
  4. Myeloma (10)
  5. Hematologic Malignancies Research (8)
  6. GME, Medicine (5)

More Groups

People
  1. Alexander Lesokhin (7)
  2. Sergio Giralt (4)
  3. Kylee Maclachlan (3)
  4. Saad Usmani (3)
  5. Sham Mailankody (3)
  6. Carl Landgren (2)

More People

Years
  1. 2025 (1)
  2. 2024 (3)
  3. 2023 (1)
  4. 2022 (1)
  5. 2020 (2)
  6. 2018 (3)

More Years

Publications
  1. Best Practice and Research: Clinical Haematology (2)
  2. Blood (2)
  3. Annals of Pharmacotherapy (1)
  4. Cancer Cell (1)
  5. Clinical Biochemistry (1)
  6. Clinical Lymphoma, Myeloma and Leukemia (1)

More Publications

Publishers
  1. Elsevier Inc. (4)
  2. American Society of Hematology (2)
  3. Cell Press (1)
  4. Elsevier Science, Inc. (1)
  5. Harborside Press (1)
  6. Nature Publishing Group (1)

More Publishers

Results (13)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Addition of elotuzumab to backbone treatment regimens for multiple myeloma: An updated meta-analysis of randomized clinical trials
    Journal Article

    Costa, B. A.; Costa, T. A.; Chagas, G. C. L.; Mouhieddine, T. H.; Richter, J.; Usmani, S. Z.; Mailankody, S.; Rajeeve, S.; Hashmi, H.
    Clinical Lymphoma, Myeloma and Leukemia (2025)

    Fulltext@MSK | Save
  • Clinical response and pathway-specific correlates following TIGIT–LAG3 blockade in myeloma: The MyCheckpoint randomized clinical trial
    Journal Article

    Richard, S.; Lesokhin, A. M.; Paul, B.; Kaufman, J. L.; Pianko, M.; Biran, N.; Vij, R.; Doxie, D. B.; Azeem, M. I.; Martillo, M.; more...
    Nature Cancer (2024)

    Fulltext@MSK | Save
  • The biological and clinical impact of deletions before and after large chromosomal gains in multiple myeloma
    Journal Article

    Cirrincione, A. M.; Poos, A. M.; Ziccheddu, B.; Kaddoura, M.; Bärtsch, M. A.; Maclachlan, K.; Chojnacka, M.; Diamond, B.; John, L.; Reichert, P.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Health-related quality of life in patients with triple-class exposed relapsed and refractory multiple myeloma treated with idecabtagene vicleucel or standard regimens: patient-reported outcomes from the phase 3, randomised, open-label KarMMa-3 clinical trial
    Journal Article

    Delforge, M.; Patel, K.; Eliason, L.; Dhanda, D.; Shi, L.; Guo, S.; Marshall, T. S.; Arnulf, B.; Cavo, M.; Nooka, A.; more...
    The Lancet Haematology (2024)

    Fulltext@MSK | Save
  • Interventions and outcomes of patients with multiple myeloma receiving salvage therapy after BCMA-directed CAR T therapy
    Journal Article

    Van Oekelen, O.; Nath, K.; Mouhieddine, T. H.; Farzana, T.; Aleman, A.; Melnekoff, D. T.; Ghodke-Puranik, Y.; Shah, G. L.; Lesokhin, A.; Giralt, S.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Are we ready to look beyond plasma cells in assessing high-risk smoldering myeloma?
    Editorial

    Maclachlan, K. H.; Lesokhin, A. M.
    Cancer Cell (2022)

    Fulltext@MSK | Save
  • Monoclonal antibodies in multiple myeloma: Current and emerging targets and mechanisms of action
    Review

    Wudhikarn, K.; Wills, B.; Lesokhin, A. M.
    Best Practice and Research: Clinical Haematology (2020)

    Fulltext@MSK | Save
  • Second malignancies in multiple myeloma; emerging patterns and future directions
    Review

    Maclachlan, K.; Diamond, B.; Maura, F.; Hillengass, J.; Turesson, I.; Landgren, C. O.; Kazandjian, D.
    Best Practice and Research: Clinical Haematology (2020)

    Fulltext@MSK | Save
  • Management of relapsed and refractory multiple myeloma: Novel agents, antibodies, immunotherapies and beyond
    Journal Article

    Chim, C. S.; Kumar, S. K.; Orlowski, R. Z.; Cook, G.; Richardson, P. G.; Gertz, M. A.; Giralt, S.; Mateos, M. V.; Leleu, X.; Anderson, K. C.
    Leukemia (2018)

    Fulltext@MSK | Save
  • Treatment of multiple myeloma with monoclonal antibodies and the dilemma of false positive M-spikes in peripheral blood
    Journal Article

    Murata, K.; McCash, S. I.; Carroll, B.; Lesokhin, A. M.; Hassoun, H.; Lendvai, N.; Korde, N. S.; Mailankody, S.; Landau, H. J.; Koehne, G.; more...
    Clinical Biochemistry (2018)

    Fulltext@MSK | Save